NCT00539825已完成1 期
A Randomized Double-blind, Placebo-controlled, Crossover, Dose Escalation Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK704838 and Tiotropium Bromide
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- adverse events, vital signs,12-lead ECG, Holter and ECG monitoring,lung function and clinical lab tests. These will be taken pre-dose and at multiple time points up to 48h at each treatment period.
研究概览
简要总结
GSK704838C is a potent, pan-active mAChR antagonist, which is being developed for once-daily treatment of chronic obstructive pulmonary disease (COPD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subject
- •Aged between 18-55 years inclusive.
- •Non-smokers
- •Normal spirometry
- •A signed and dated written informed consent is obtained from the subject.
- •The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •Available to complete the study.
- •The subject is =50kg with a body mass index within the range 19.0 to 29.9 kg/m2 inclusive.
- •Response to ipratropium bromide
排除标准
- •Any clinically relevant and important abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or ECG (12-lead or Holter).
- •A history of breathing problems
- •A mean QTc(B) value > 450ms, the QTc(B) of the 3 screening ECGs are not within 10% of the mean, a PR interval outside the range 90-210ms or an ECG that is not suitable for QT measurements at screening.
- •A history of elevated resting blood pressure or a mean blood pressure higher than 140/90 mmHg at screening.
- •A mean heart rate outside the range 40-90 bpm inclusive at screening.
- •History of use of tobacco- or nicotine-containing products within 6 months of screening, and/or positive urine cotinine test results at screening.
- •Where participation in the study would result in donation of blood in excess of 500mL within a 56 day period at screening.
- •The subject is currently taking regular (or a course of) medication, whether prescribed or not, including herbal remedies such as St John's Wort etc.
- •The subject has taken:
- •prescription medications for 14 days prior to first dose of study drug, or
- •Over-the-counter (OTC) medications/preparations (including herbal remedies, etc.) excluding simple analgesics for 48 hours prior to first dose of study drug, unless it is judged by the Investigator not to compromise the subject's safety or influence the outcome of the study.
- •The subject has participated in a study with a new molecular entity or any other trial within a period of 3 months prior first dose of study drug.
- •The subject has tested positive for hepatitis C antibody (third generation enzyme immunoassay), hepatitis B surface antigen or HIV antibodies (if tested according to site SOP's) at screening.
- •The subject has tested positive for drugs-of-abuse at screening.
- •The subject has tested positive for urine alcohol (including ethanol) at screening.
- •The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.
- •The subject is unable to use the DISKUS™ and/or HandiHaler inhaler devices correctly at screening.
- •The subject has a suspected history of alcohol abuse within the six months previous to the screening visit.
- •The subject has a known allergy or hypersensitivity to magnesium stearate, milk protein or the excipient lactose monohydrate, iodine, ipratropium bromide, tiotropium bromide, atropine and/or any of its derivatives.
- •The subject has a significant clinical history of prostatic hypertrophy or narrow angle glaucoma.
- •The subject has received an allogeneic bone marrow transplant.
- •The subject has claustrophobia that may be aggravated by entering the whole body plethysmography cabinet.
结局指标
主要结局
adverse events, vital signs,12-lead ECG, Holter and ECG monitoring,lung function and clinical lab tests. These will be taken pre-dose and at multiple time points up to 48h at each treatment period.
次要结局
- - Plasma and urine concentrations of GSK704838 and derived pharmacokinetic parameters over 48h post-dose. - Serial sGaw, Raw and FEV1 measurements over 24h post-dose.
- Serial specific airway conductance (sGaw), Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity measurements (FVC) over 24 hours post-dose of GSK704838 and tiotropium bromide.
- Serial sGaw measurements over 48 hours for the last period in each cohort dose of GSK704838 and tiotropium bromide.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Effect of GSK1160724 In Healthy VolunteersPulmonary Disease, Chronic ObstructiveNCT00555022GlaxoSmithKline21
已完成
1 期
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy VolunteersPulmonary Disease, Chronic ObstructiveNCT00475436GlaxoSmithKline36
已完成
1 期
Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00279019GlaxoSmithKline31
已完成
2 期
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.Pulmonary Disease, Chronic ObstructiveNCT00453479GlaxoSmithKline23
已完成
2 期
Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00376714GlaxoSmithKline45